Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ARCTURUS THERAPEUTICS HOLDINGS INC.

(ARCT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc. is a clinical-stage messenger ribonucleic acid (mRNA) medicines company. The Company is engaged in the development of infectious disease vaccines, and significant opportunities within liver and respiratory rare diseases. The Company offers RNA medicines, RNA drug substance and nanoparticle-formulated drug products. The Company's technologies include Self-Transcribing and Replicating RNA (STARR) and lipid nanoparticle delivery system (LUNAR). The Company has developed the STARR technology platform which combines self-replicating RNA with LUNAR into a single solution. The products under developmental stage using STARR technology are ARCT-021 (LUNAR-COV19 Vaccine), LUNAR-FLU, ARCT-810 (LUNAR - ornithine transcarbamylase (OTC)) and ARCT-032 (LUNAR - cystic fibrosis (CF)). The Company has a pipeline of seven drug candidates in late-stage discovery and early stage development.

Number of employees : 118 people.
Sales per Business
2020
RNA Therapeutics9.54100%
USD in Million
Sales per region
20192020Delta
Israel20.79100%9.54100% -54.12%
USD in Million
Managers
Name Title Age Since
Joseph E. Payne President, Chief Executive Officer & Director 48 2013
Andrew H. Sassine Chief Financial Officer & Director 55 2019
Padmanabh Chivukula, Dr. Secretary, Chief Operating & Scientific Officer 41 2013
Steven G. Hughes, Dr. Chief Medical Officer 53 -
Dushyant B. Varshney, Dr. Chief Technology Officer - 2021
Peter Farrell Chairman 78 2018
James F. Barlow Independent Director 61 2018
Magda Marquet, Dr. Independent Director 61 2018
Edward W. Holmes, Dr. Independent Director 79 2019
Neda Safarzadeh Investor Relations & Media Contact - -
Members of the board
Name Title Age Since
Peter Farrell Chairman 78 2018
James F. Barlow Independent Director 61 2018
Magda Marquet, Dr. Independent Director 61 2018
Joseph E. Payne President, Chief Executive Officer & Director 48 2013
Andrew H. Sassine Chief Financial Officer & Director 55 2019
Edward W. Holmes, Dr. Independent Director 79 2019
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 26,360,521 22,676,356 86.0% 0 0.0% 86.0%
Shareholders
NameEquities%
Federated Global Investment Management Corp. 3,045,288 11.6%
ARK Investment Management LLC 2,853,258 10.8%
HealthCor Management LP 1,594,452 6.06%
Joseph E. Payne 1,475,097 5.60%
SSgA Funds Management, Inc. 1,470,341 5.58%
Nikko Asset Management Americas, Inc. 1,358,532 5.16%
Nikko Asset Management Co., Ltd. 1,358,532 5.16%
Ultragenyx Pharmaceutical Inc. 1,200,000 4.56%
The Vanguard Group, Inc. 1,079,091 4.10%
Fidelity Management & Research Co. LLC 1,072,977 4.08%
Holdings
NameEquities%Valuation
VALLON PHARMACEUTICALS, INC. (VLON) 843,750 12.4% 4,016,250 USD
Brand Portfolio
In partnership withAllbrands.markets
More brands of Arcturus Therapeutics Holdings Inc.